A Phase II trial of split, low-dose docetaxel and low-dose capecitabine: a tolerable and efficacious regimen in the first-line treatment of patients with HER2/neu-negative metastatic breast cancer. [electronic resource]
Producer: 20080909Description: 162-7 p. digitalISSN:- 1526-8209
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- Breast Neoplasms -- drug therapy
- Capecitabine
- Deoxycytidine -- administration & dosage
- Disease-Free Survival
- Docetaxel
- Female
- Fluorouracil -- administration & dosage
- Humans
- Kaplan-Meier Estimate
- Middle Aged
- Receptor, ErbB-2 -- metabolism
- Taxoids -- administration & dosage
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.